Valirx is an international biotechnology cancer focused company, which is in clinical trials and which has three classes of drugs in development.  These include Peptides, Small Molecules or Small Chemical Entities and Gene Silencing Methods, all of which are addressing unmet clinical needs.

We are seeking to respond to research that shows that there is an increasingly high demand for new personalised medicines and services, which enhance patient care, achieve faster diagnoses and substantially improve treatment outcomes in a cost effective manner.

Valirx is a growing company with a clear business model, with extensive world-wide patent filings and with intellectual property that originates from World-class institutions.   We look to reduce risk in new product development through a rigorous clinical and commercial due diligence process, selecting those drug candidates and technologies that illicit evidence-based potential to address the unmet needs of the market. We then seek to maximise returns to shareholders by adding value at the earlier development stage where value increases per investment unit are the greatest.

The Valirx management team is a mixture of entrepreneurial scientists and business professionals, all with experience of developing medical life science companies. The team is also experienced at transferring technologies and products into the commercial arena to generate revenue and grow shareholder value.